PEARLS: A phase II/III trial of primary radiotherapy for androgen sensitive prostate cancer patients with lymph nodes

Trial summary:

PEARLS aims to determine whether extended field IMRT to the prostate, pelvis and para-aortic region improves metastasis-free survival compared to standard field IMRT to the prostate ± pelvis in patients with node positive prostate cancer. PSMA PET-CT imaging is used to determine the extent of lymph node disease and to identify involved lymph nodes for an integrated RT boost.  893 patients will be recruited from 30 UK sites over 6.5 years.

RT QA summary:

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.

QA ProcessQA ActivityRequired for TrialAdditional Details
Pre-AccrualFacility QuestionnaireStreamlined
Outlining Benchmark CaseStreamlined
Planning Benchmark CaseExtended field arm case
Dummy Run
During AccrualIndividual Case ReviewFor extended field arm
Data collectionAll patients
QA StreamliningPACE, PIVOTALboost and PACE-NODES trials

RTTQA contact:

Chief investigator: Dr Julia Murray

Sponsor: The Institute of Cancer Research (

Funder: Cancer Research UK